Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Spezial Report: NASDAQ-FinTech mit 3.000% Wachstum und 500% Kurs-Chance!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
17 Leser
Artikel bewerten:
(0)

WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008

Earnings Conference Call to be held on March 13, 2008 at 9:00 am (Eastern) / 6:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong)

SHANGHAI, China, Feb. 21 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi PharmaTech" or "the Company"), the leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release unaudited financial results for the fourth quarter and full year ended December 31, 2007 after the US market close on Wednesday, March 12, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations page of its website at http://www.wuxipharmatech.com/ .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 9:00 am (Eastern) / 6:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong) on Thursday, March 13, 2008 to discuss its 2007 fourth quarter and full year financial results and recent business activity. The conference call may be accessed by calling:

United States Toll Free: +1-888-596-2633 Toll: +1-913-312-1234 China, Northern Region Toll Free: +10-800-714-0970 China, Southern Region Toll Free: +10-800-140-0945 Hong Kong Toll Free: +800-965-503 United Kingdom Toll Free: +0808-101-1402

A telephone replay will be available shortly after the call until April 12, 2008 at (US) +1-888-203-1112/ (HK) +800-901-108 / (China, Southern Region) +10-800-140-1178 / (China, Northern Region) +1-719-457-0820 / (UK) +0808-101- 1153. Passcode: 2224172.

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxipharmatech.com/ .

About WuXi PharmaTech (Cayman) Inc.

WuXi PharmaTech, headquartered in Shanghai, China, is the leading global pharmaceutical, biotechnology and medical device R&D outsourcing company. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory, research manufacturing, biologics testing and manufacturing services throughout the drug and medical device research and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device research and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. For more information, please visit: http://www.wuxipharmatech.com/ .

For more information, please contact: Investor Contact: Dr. Hai Mi, Vice President, Corporate Communications WuXi PharmaTech Co., Ltd Tel: +86-21-5046-3726 Email: ir@pharmatechs.comInvestor Relations (US): Mahmoud Siddig, Director Taylor Rafferty Tel: +1-212-889-4350 Email: Pharmatechs@taylor-rafferty.comInvestor Relations (HK): Ruby Yim, Managing Director Taylor Rafferty Tel: +852-3196-3712 Email: Pharmatechs@taylor-rafferty.comMedia Contact: John Dooley Taylor Rafferty Tel: +1-212-889-4350 Email: Pharmatechs@taylor-rafferty.com

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2008 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.